Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biomarkers - From Research To Commercialization


Exploring Blood based Biomarkers for Neurodevelopmental Diseases: Challenges and New Approaches

Aditi Bhattacharya, Reader(E)- Center for Brain Development and Repair, Institute for Stem Cell Biology and Regenerative Medicine

A significant limitation for neuropsychiatry is the lack of reliable biomarkers for any disease condition that correlate well with behavioral symptoms. For instance, drug discovery efforts in ASD (especially FXS) have suffered setbacks in trials because of a large placebo effect in behavioral tests. While behavioral assessments are an indispensable part of any future trial and medical practice, it is clear that no one measure will likely be able to track all improvements and that a combination of behavioral assessments, with unbiased molecular markers may have the required power. The current status of research into molecular biomarkers suffers from several limitations including  inaccessibility of the brain as sample tissue, lack of substrate that is dynamic enough in the span of few weeks to accurately represent changes in disease modifications in a trial setting and finally limited clinical history for said marker is available. I will discuss using my work with leveraging proteomic data derived from intact brain tissue to identify blood based candidate proteins for the discovery of molecular barcodes in Fragile X Syndrome, a leading genetic cause of intellectual disability and Autism.

Add to Calendar ▼2018-05-24 00:00:002018-05-25 00:00:00Europe/LondonBiomarkers - From Research To CommercializationBiomarkers - From Research To Commercialization in